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Background and purpose: The influence of glucocorticoid induced hyperglycemia on survival in patients
with metastatic spinal cord compression (MSCC) is unknown.
Materials and methods: In a prospective, observational cohort study 131 patients with MSCC referred to
radiotherapy, 30 Gray (Gy) in 10 fractions, and treated with 100 mg prednisolone a day were followed
with daily blood glucose measurements during radiotherapy.
Results: During follow-up a total of 56 patients 43% (95% CI = 35–52%) presented plasma glucose values
diagnostic of diabetes. Sixteen patients who developed diabetes were treated with insulin, 12% (95%
CI = [6%; 18%]) of the total population. The patients developing diabetes with need for insulin therapy
during glucocorticoid therapy had a significantly increased mortality compared to those with normal
glucose metabolism and with diabetes without need for therapy, hazard ratio = 2.1 (95% CI = 1.08–4.09,
p = 0.0285).
Discussion: To our knowledge this is the first prospective study to describe the influence of glucocorticoid
induced diabetes on survival in patients with MSCC from different primary tumors.
Conclusions: The results indicate that development of diabetes during high-dose glucocorticoid therapy
needing insulin treatment in patients with MSCC from different primary tumors is associated with
reduced survival.
 2018 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Patients with metastatic spinal cord compression (MSCC) are
treated with high doses of glucocorticoids to reduce local edema
from the diagnosis is suspected and during radiotherapy [1].
Glucocorticoids may induce hyperglycemia and diabetes because
of insulin resistance, decreased pancreatic insulin secretion and
increased hepatic gluconeogenesis [2]. The risk of developing dia-
betes during high-dose glucocorticoid therapy in cancer patients
ranges between 11% and 34.3% [3–5] in different patient categories
and with divers definitions of diabetes.A potential impact of diabetes on survival in cancer patients
remains controversial. Thus, preexisting diabetes at the time of
cancer diagnosis increase all-cause mortality [6] but there is con-
tradicting evidence as to whether hyperglycemia and diabetes,
preexisting or induced by glucocorticoids, affect survival in cancer
patients negatively [7–11] or not [12,13]. This may be explained by
pre-existing diabetes which potentially may contribute to excess
mortality both through already established cardiovascular disease
and through metabolic pathways including catabolism and
increased oxidative stress. In contrast, glucocorticoid-induced
diabetes is mainly a metabolic disorder. No previous studies have
excluded cancer patients with preexisting diabetes and assessed
the influence on mortality of glucocorticoid induced diabetes
per se.
We performed a prospective, observational cohort study aiming
to determine the incidence and consequence of glucocorticoid
induced diabetes in 131 patients with MSCC [14]. In this analysis
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induced diabetes in previously non-diabetic cancer patients with
MSCC influence survival.Materials and methods
Design
Patients with a tentative diagnosis of MSCC are referred to the
Department of Radiation Oncology at hospital X in city X 24 h a
day 7 days a week from country X, an area with approximately
2.4 million inhabitants. From May 2013 to December 2014 we
included patients in a prospective, observational cohort study on
glucocorticoid induced diabetes in this department.
Once the diagnosis of MSCC is confirmed by magnetic resonance
imaging (MRI), the patient is conferred with the Spine Unit to
decide whether surgery is a possibility or not [15]. Approximately
20% of the patients are offered surgery before radiotherapy [16]
and the remainder are offered radiotherapy alone. If the patient
is believed to live for more than six months, based on the clinical
evaluation by the oncologist and a scoring system (Tokuhashi
Revised score [17,18]), the patient is treated with 30 Gy in 10 frac-
tions. The patients are offered a single fraction of 8–10 Gy if they
are expected to live for less than three months.
High-dose glucocorticoid therapy has proven beneficial as an
adjunct to radiotherapy [1] and is most often initialized in the local
hospital, alternatively prescribed at the first visit at hospital X. The
standard dose was 300 mg prednisolone a day during radiotherapy.
Radiotherapy is given on an outpatient basis and patients who
need to be hospitalised are admitted to their local hospital in the
treatment period.
We followed the patients who were referred to 30 Gy in 10 frac-
tions and treated with high dose glucocorticoid [19], 100 mg
prednisolone per day or an equivalent dose of another
glucocorticoid.
All procedures followed were in accordance with the Helsinki
Declaration [20], the study was approved by The Regional Commit-
tee on Health Research Ethics (file number H-4-2012-004) and
reported to the Danish Data Protection Agency (file number HIH-
2011-22). Oral and written information was given by the primary
investigator (HS), who also obtained written, informed consent to
participate.Subjects
Cancer patients with a histologically confirmed diagnosis, were
eligible for inclusion if they were 18 years or more of age, were
diagnosed with MSCC, treated with 100 mg prednisolone daily
and were referred to radiotherapy treatment with 30 Gy in 10 frac-
tions. Known diabetes was the only exclusion criterion and the
classification was based on self-reporting from the patients, pre-
scription of antidiabetic medication according to medical records
and measurement of HbA1c at baseline (in 118 out of 131
patients).Fig. 1. Illustration of the multistate model.Clinical and laboratory data
At the time of inclusion, we obtained information on age, sex,
height and body weight, primary tumor, medical history, diabetes
in first- and second-degree relatives, tobacco and alcohol con-
sumption and medications data. Venous blood samples were col-
lected and performance status (PS) was assessed using the
toxicity and response criteria of the Eastern Cooperative Oncology
Group (ECOG) [21]. On the last day of radiotherapy venous bloodsamples were repeated. The dose of prednisolone was registered
on a daily basis.Monitoring of blood glucose and classification of diabetes
During the subsequent 12 days one to four capillary blood
glucose measurements daily were performed using a Medisense
Precision XceedPro glucosemeter (Abbott Diabetes Care Inc.
Alameda, USA). In inpatients, we aimed at three measurements a
day in their local hospital and one measurement in the Section of
Radiotherapy, while outpatients had one measurement in
conjunction with radiotherapy.
Diabetes was defined according to a modification of WHO
guidelines from 2006: two random plasma glucose measurements
11.1 mmol/L [22]. Fasting glucose measurements and oral glu-
cose tolerance test were not feasible in this acute setting and due
to the short time of observation diabetes defined by HbA1c was
not an option.
There were no study instructions on treatment of hyper-
glycemia or diabetes. The decision to initiate glucose lowering
therapy was taken by the physicians at the department where
the patient was admitted following local guidelines.
Insulin was the preferred choice for all patients who had
glucose lowering therapy. Patients were defined as having insulin
treated diabetes from their first injection of insulin.Survival data
Inclusion took place between May 2013 and December 2014.
5 months after inclusion was ended, in May 2015, we registered
if the patients were dead or alive using the medical records and
the Central Office of Civil Registration.Statistics
The study was powered to detect a prevalence of glucocorticoid
induced diabetes of 15% with an accuracy of ±5% (140 participants)
and subsequently we explored survival for patients with and
without diabetes.
Kaplan-Meier estimates stratified by primary tumor were used
to describe survival for all the patients. Log-rank tests were used to
test for equality of the survival functions and pairwise comparisons
were adjusted for multiplicity by Holm’s method.
The effect of glucocorticoid induced diabetes on mortality was
modeled by the multistate model shown in Fig. 1. The boxes in
the figure represent the four different states that a patient can be
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sent the possible transitions between the states.
At time zero, determined by start of prednisolone treatment, all
patients belong to the initial state (alive without diabetes). Over
time, each patient can then either die without getting diabetes or
develop diabetes (either by definition or insulin treated) and then
subsequently move to the deceased state. Deaths were censored at
the end of study (May 2015) and diabetes events were censored 12
days after start of prednisolone treatment.
The parameters of interest are the three transition-specific haz-
ard functions going to the absorbing death state. The transition
probabilities were estimated by the Aalen-Johansen estimator
and the equality of the associated transition hazards was tested
under a proportionality assumption. The covariates (age, sex, body
mass index (BMI), PS, primary tumor and C-reactive protein (CRP))
were included through a stratified Cox model where each stratum
corresponds to a transition and the covariates were allowed to
have different effects across the strata.Results
Recruitment/response
Of 324 patients assessed for eligibility 140 were recruited (43%)
and 131 were included in the analyses on incidens, risk factors and
time course. One patients with overt diabetes, HbA1c = 79 mmol/
mol, was excluded from the survival analysis, further seven with
slightly elevated values were included as a single HbA1c measure-
ment is not diagnostic of diabetes [23]. For baseline characteristics
see Table 1.Table 1
Baseline characteristics. IQR = interquartile range.
Variable All No diabete
N (%) 131 (100) 75 (57)
Female sex (%) 42 (32) 43 (33)
Age (years), mean (min; max) 68 (46; 88) 68 (48; 88
BMI (kg/m2), mean (min; max) 25 (14; 44) 25 (15; 44
N = 73
Performance status (%)
0 6 (4) 6 (8)
1 52 (40) 36 (48)
2 44 (34) 18 (24)
3 29 (22) 15 (20)
Primary tumor (%)
Lung 36 (27) 22 (29)
Breast 25 (19) 16 (21)
Prostate 31 (24) 14 (19)
Others 39 (30) 23 (31)
Brain metastases (%) 5 (4) 4 (5)
Lung metastases (%) 51 (39) 35 (47)
Liver metastases (%) 30 (23) 16 (21)
Bone metastases (%) 129 (99) 74 (99)
Hospitalisation or not
Outpatient 56 (43) 41 (55)
Inpatient 53 (40) 21 (28)
Alternating 22 (17) 13 (17)
Prednisolone start dose, mg,
mean (min; max)
261 (100; 2500) 234 (100;
Cumulated dose of prednisolone
in twelve days treatment,
mg, mean (min; max)
2919 (1000; 6750) 2835 (120
Daily prednisolone dose in
twelve days treatment,
mg, mean (min; max)
247 (83; 563) 240 (100;
Number of plasma glucose
measurements, median (IQR)
9 (8–20) 8 (7–12)Characteristics of the sample
The patients were grouped according to primary tumor in 4 cat-
egories, lung cancer n = 36 (27%), breast cancer n = 25 (19%), pros-
tate cancer n = 31 (24%) and other cancer forms n = 39 (30%)
including unidentified tumors and tumors of unknown origin.
During follow-up a total of 56 patients (43%, 95% CI = [35%;
52%]) presented plasma glucose values diagnostic of diabetes. 40
(31%, 95% CI = [23%; 39%]) patients had diabetes that was left
untreated and 16 patients (12%, 95% CI = [6%; 18%]) were treated
with insulin [14]. No patients received oral antidiabetic medicine.Diabetes and mortality
In six months (180 days), from the first day of prednisolone, 78
(60%) of the patients died: 28 (78%) patients with lung cancer, 15
(48%) patients with prostate cancer, 5 (20%) patients with breast
cancer and 30 (77%) the patients with other cancer forms, see
Fig. 2. The overall p-value for equality of survival function was less
than 0.0001 and the pairwise comparisons showed that all survival
functions were significantly different from each other at the 5%
level except for lung cancer vs. other cancer type and breast cancer
vs. prostate cancer with adjusted p-values equal to 0.4406 and
0.1481 respectively.
Out of the 75 patients that did not develop diabetes 57 (76%)
died, out of the 40 patients with untreated diabetes 28 (70%) died,
and out of the 16 patients with diabetes treated with insulin 14
(87.5%) died.
At the end of study in May 2015, 32 patients were still alive and
had a median follow up of 234 days (min–max; 159–723)s Untreated diabetes Diabetes treated with insulin
40 (31) 16 (12)
45 (34) 31 (24)
) 68 (46; 87) 69 (50; 86)
) 24 (14; 31) 25 (18; 33)
N = 38 N = 15
0 0 (0)
13 (32) 3 (19)
19 (48) 7 (44)
8 (20) 6 (37)
10 (25) 4 (25)
7 (17) 2 (13)
12 (30) 5 (31)
11 (28) 5 (31)
0 1 (6)
13 (33) 3 (19)
9 (23) 5 (31)
39 (98) 16 (100)
15 (38) 0
19 (47) 13 (81)
6 (15) 3 (19)
350) 307 (100; 2500) 275 (150; 300)
0; 3650) 3040 (1000; 6750) 2966 (1400; 3600)
304) 255 (83; 563) 259 (150; 300)
13 (8–28) 30 (18–33)
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Fig. 2. Survival based on primary tumor in 131 patients with metastatic spinal cord compression treated with high doses of glucocorticoids and followed for a mean of 355
days. The numbers under the figure refer to the number of patients at risk at the time points above stratified by tumor group.
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Fig. 3. Nonparametric estimates of the transition probabilities to death according to three states: No diabetes, diabetes by definition and insulin treated diabetes.
22 H. Schultz et al. / Clinical and Translational Radiation Oncology 11 (2018) 19–25
H. Schultz et al. / Clinical and Translational Radiation Oncology 11 (2018) 19–25 23Fig. 3 shows the estimated transition probabilities in the unad-
justed model. Under the proportionality assumption the mortali-
ties for patients that did not develop diabetes and the patients
with diabetes left untreated were alike with a hazard ratio of
0.99 (95% CI = 0.63–1.56, p = 0.9698). Patients developing gluco-
corticoid induced diabetes with need for insulin therapy had a sig-
nificantly increased mortality compared to those with normal
glucose metabolism and with diabetes without need for therapy,
hazard ratio = 2.1 (95% CI = 1.08–4.09, p = 0.0285).
Tumor group significantly affected the transition hazards from
alive without diabetes to death, from untreated diabetes to death
and from insulin treated diabetes to death (p-values for likelihood
ratio test equal to 0.0151, 0.0221 and 0.051 respectively). Patients
with lung cancer had the highest mortality. Furthermore, there
was a significant positive association between CRP and transition
from alive without diabetes to death (p = 0.0124). Table 2 shows
the estimated hazard ratios and 95% confidence intervals. None
of the other covariates showed any significant effects on the tran-
sition hazards. We note that with only 14 observed events in the
transition from insulin treated diabetes to death there is little
information available for adjustments.
The baseline hazards function in the Cox model for insulin trea-
ted diabetes was still significantly different from the baseline mor-
tality of patients with normal glucose metabolism and for diabetes
without need for therapy when adjusting for tumor group,
p = 0.0017.
To assess potential confounding from misclassification: dia-
betes at baseline or not, need for insulin therapy or not, inpatient
or not, we made a sensitivity analysis based on whether the
patients had any glucose measurement >15 mmol/L during the
observation period. This analysis only included patients with
HbA1c <48 mmol/mol. A log-rank test showed that patients who
had at least one glucose measurement >15 mmol/l (n = 17) had sta-
tistically significant worse survival, p = 0.00639, Fig. 4. This is also
true if we include all the patients in the analysis or remove only the
patient with HbA1c = 79 mmol/mol at baseline.
Discussion
Main findings
In this study, which is the first to assess the isolated impact of
glucocorticoid induced diabetes on mortality in MSCC, develop-
ment of diabetes needing insulin treatment was associated with
a doubled mortality risk. The mortality of the patients as a whole
is comparable to other cohorts of patients with MSCC in Danish
hospitals [16,24] and not influenced by other risk factors in the
adjusted model.
Comparison of findings with those reported in the literature
In a meta-analysis Barone et al. conclude that preexisting type
1 and 2 diabetes in cancer patients at the time of diagnosis was
associated with an HR of 1.41 for the risk of all-cause mortality
compared with individuals without diabetes. The meta-analysisTable 2
Impact of tumor group and CRP on transitions between the states. Patients with lung can
No diabetes? Death Un
Lung cancer 1 (ref.) 1 (
Breast cancer 0.326 [0.139; 0.765] 0.2
Prostate cancer 0.367 [0.157; 0.859] 0.5
Other cancer type 0.767 [0.389; 1.513] 1.9
CRP 1.011 [1.002; 1.019] –included 23 studies with patients with various types of cancer
[6]. Suggested explanations for the increased all-cause mortality
are several: Facing a cancer diagnosis patients with diabetes
and their doctors maybe don’t pay enough attention to the man-
agement of hyperglycemia, blood pressure and dyslipidemia; the
diabetic patients with comorbidity often may not be offered the
same anti-cancer treatment as the non-diabetic patients and
maybe they respond less well; tumor cell proliferation may be
increased in a hyperglycemic, hyperinsulinaemic environment
and finally diabetes in itself carries an increased risk of cardiovas-
cular death [6].
Studies looking at hyperglycemia and diabetes in cancer
patients, with and without preexisting diabetes and treated with glu-
cocorticoids or not, predominantly find a negatively influence on
survival. Patients with grade III and IV astrocytomas and persistent
hyperglycemia had a median survival of 5 months compared to
patients without hyperglycemia who had a median survival of
11 months. Hyperglycemia was secondary to preexisting diabetes
in 7 patients (25%) and secondary to Decadron use in 21 patients
(75%) [10]. Derr et al. found an inverse relationship between mean
glucose level and survival period in patients with newly diagnosed
glioblastoma multiforme with and without preexisting diabetes,
that is the higher the mean glucose the shorter the survival [8].
In low grade gliomas, patients with persistent outpatient hyper-
glycemia had a five year survival rate of 43% versus 84% in the
group without hyperglycemia, a result that remained statistically
significant after controlling for various other factors known to
influence survival [7]. In a prospective study, again including
patients with preexisting diabetes, of hematologic patients with
acute lymphocytic leukemia (ALL) who had high dose glucocorti-
coid as part of a chemotherapy regime, hyperglycemia was associ-
ated with a shorter time to remission, an increase in overall
mortality and an increased risk for developing complicated infec-
tions [11].
No previous studies have focused solely on glucocorticoid
induced diabetes and survival. As mentioned in the introduction
the distinction between preexisting diabetes and glucocorticoid
induced diabetes is however important because cardiovascular dis-
ease, along with other comorbidity, as a complication to long
standing diabetes might influence survival in patients with preex-
isting diabetes. Glucocorticoid induced diabetes seems to be
mainly characterized by metabolic changes as described by Sim-
mons et al. who found that patients with glucocorticoid induced
diabetes had less family history of diabetes, weighed less, had less
retinopathy and had significantly fewer macrovascular complica-
tions than patients with type 2 diabetes receiving or not receiving
glucocorticoid [25]. Further supporting a metabolic effect of hyper-
glycemia on survival in cancer, Chaichana et al., mentioned above,
found that persistent outpatient hyperglycemia (not in diabetic
levels), is associated with decreased survival in patients with low
grade glioma, also when excluding patients with preexisting dia-
betes from analysis and patients who were on steroids in the
observation period. This indicates that a metabolic state with
hyperglycemia, even in the absence glucocorticoids, may also wor-
sen the prognosis [7].cer generally have the highest mortality in each transition.
treated diabetes? Death Insulin treated diabetes? Death
ref.) 1 (ref.)
26 [0.045; 0.133] 0.048 [0.004; 0.578]
87 [0.194; 1.765] 0.287 [0.068; 1.231]
97 [0.650; 6.134] 0.182 [0.033; 1.003]
–
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Fig. 4. Sensitivity analysis. A log-rank test showed that patients who had at least one glucose measurement >15 mmol/l (n = 17) had statistically significant worse survival, p
= 0.00639. This analysis only included patients with HbA1c <48 mmol/mol.
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The main strength of our study was that data on glucocorticoid
induced diabetes was systematically gathered prospectively and
more detailed than in previous studies, making diabetes classifica-
tion of patients with diabetes by definition more certain.
Patients were categorized as having insulin treated diabetes
based on the local doctor’s decision to start treatment. There were
no study instructions when to give insulin and that might have
been a limitation due to misclassification. The Joint British Dia-
betes Societies for inpatient care (JBDS-IP) recommend that if
blood glucose values in patients treated with glucocorticoids are
consistently greater than 12 mmol/L antidiabetic treatment is
instituted, but in specific clinical situations (e.g. end of life care)
you might be less conservative and aim for values below 15
mmol/L [26]. Out of 16 patients treated with insulin in our study,
14 had blood glucose measurements >15 mmol/l before insulin
treatment was initiated thus reflecting typical clinical recommen-
dations. The last two patients had insulin after blood glucose mea-
surements >14.0 and 14.4 mmol/l. So although the decision to
initiate insulin treatment was based on clinical judgement from
different physicians we believe that the patients with need for
insulin therapy were overall correctly identified. Furthermore the
analyses resulted in similar outcome when using insulin therapy
or plasma glucose >15 mmol/l as grouping criterion.
The patients were homogeneous in the sense that they were all
referred to the same radiotherapy regimen and had the same dose
of glucocorticoids, but compared to the regimen in other radiother-
apy clinics the dose of glucocorticoid was relatively high. The
prospective design also made it possible to systematically collect
data on risk factors for diabetes and PS.
The study was powered to identify the incidence of glucocorti-
coid induced diabetes and this secondary analysis on survival is
limited by the small number of patients with glucocorticoid
induced diabetes although the results reach statistical significance.Conclusions
In the present study of patients with MSCC of different tumor
origin development of glucocorticoid induced diabetes needing
insulin therapy during fractionated radiotherapy reduced survival
significantly. This is the first study to assess the influence on sur-
vival of glucocorticoid induced diabetes since patients with known
preexisting diabetes were excluded. The results suggest a meta-
bolic effect of hyperglycaemia on mortality or alternatively a com-
mon underlying mechanism simultaneously promoting diabetes
and mortality. This question warrants a trial assessing the effect
of treatment of glucocorticoid induced diabetes on survival in can-
cer patients.Conflict of interest statement
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